Nagashima H, Fukuhara T, Utsumi Y, Suzuki A, et al. A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study. Eur J Cancer 2025;229:115693.
PMID: 40957291